Zobrazeno 1 - 10
of 72
pro vyhledávání: '"M Agelidou"'
Autor:
Dimitris Mavroudis, Nikos Kentepozidis, John Souglakos, Charalambos Christofillakis, Athanasios Kotsakis, Vassilis Georgoulias, Stelios Giassas, George Samonis, Athanasios Karampeazis, M. Agelidou, Alexandra Voutsina, Lambros Vamvakas, Sofia Agelaki, Pavlos Papakotoulas, Ageliki Rapti
Publikováno v:
Cancer. 119:2754-2764
BACKGROUND: In this superiority study, pemetrexed was compared with erlotinib in pre-treated patients with metastatic non–small cell lung cancer (NSCLC). METHODS: Patients with stage IIIB/IV NSCLC who progressed after first-line or second-line trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33ef7eaf8c6a47853703909141143ba9
https://doi.org/10.1002/cncr.28132
https://doi.org/10.1002/cncr.28132
Autor:
Leonidas Chelis, Sophia Agelaki, A. Kotsakis, George Samonis, L. Vamvakas, A. Soultati, Nikolaos K. Kentepozidis, P. Papakotoulas, Z. Zafiriou, M. Agelidou, V. Georgoulias, Ch. Christophylakis
Publikováno v:
Cancer Chemotherapy and Pharmacology. 71:605-612
The docetaxel/cisplatin (DC) combination is an active regimen against advanced/metastatic non-small-cell lung cancer (NSCLC), and bevacizumab (B) improves the efficacy of frontline chemotherapy. This phase II study was designed in order to explore th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e4722056dd8af5ccd111bdc6f2875db
https://doi.org/10.1007/s00280-012-2037-1
https://doi.org/10.1007/s00280-012-2037-1
Autor:
Giannis Mountzios, Dora Hatzidaki, Emmanouil Kontopodis, Nikolaos Vardakis, Niki Karachaliou, A. Kotsakis, Evagelos Popis, M. Agelidou, Christos Emmanouilidis, Vassilis Georgoulias
Publikováno v:
Lung Cancer. 77:146-150
Introduction Therapeutic options for patients with relapsed, chemo-resistant small-cell lung cancer (SCLC) are limited. Since paclitaxel has demonstrated single-agent activity in the second-line setting of SCLC and angiogenesis seems to play an impor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::725f3bb7ebd00d43207b390aacfed69a
https://doi.org/10.1016/j.lungcan.2012.02.002
https://doi.org/10.1016/j.lungcan.2012.02.002
Autor:
Vassilis Georgoulias, M. Agelidou, Ioannis Boukovinas, Nikolaos Androulakis, A. Agelidou, Charalambos Christophyllakis, Stelios Giassas, X. Tsiafaki, Vassilis Chandrinos, Athanasios G. Pallis, Georgia Pavlakou, Aris Polyzos, Nikolaos Kentepozidis, Lambros Lamvakas, Stelios Kakolyris, Sophia Agelaki
Publikováno v:
Journal of Thoracic Oncology. 3:505-510
IntroductionThirty to 40% of patients with non-small cell lung cancer (NSCLC) are older than 70 years and rarely are enrolled in clinical trials. Moreover, in clinical practice, >75% of patients older than 65 years with metastatic NSCLC never receive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0020327429199ead8bc7fe0dd9cad875
https://doi.org/10.1097/jto.0b013e31816b4b32
https://doi.org/10.1097/jto.0b013e31816b4b32
Autor:
V. Georgoulias, A. Argyraki, A. Geroyianni, C.-H. Christophylakis, N. Karvounis, S. Kakolyris, A. Agelidou, Charalambos Kouroussis, E. Tsaroucha, M. Agelidou, M. Veslemes, Nikos Androulakis
Publikováno v:
Lung Cancer. 53:59-65
Summary Purpose To evaluate the efficacy and tolerance of a cisplatin plus etoposide regimen followed by thoracic radiotherapy (TRT) and paclitaxel plus cisplatin consolidation chemotherapy in patients with limited stage small cell lung cancer (SCLC)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60971d6395abe38f95d1dc109e8d0ffe
https://doi.org/10.1016/j.lungcan.2006.03.011
https://doi.org/10.1016/j.lungcan.2006.03.011
Autor:
Vassilis Georgoulias, A. Agelidou, M. Agelidou, Evaggelos E Tselepatiotis, Aleka Gerogianni, Kostas K Syrigos, M. Veslemes, John J Boukovinas, Michail Ignatiadis, Georgia Pavlakou, Dimitris Mavroudis, John J Nikolakopoulos
Publikováno v:
Clinical Lung Cancer. 7:183-189
BACKGROUND: This trial was designed to compare the efficacy and toxicity of sequential versus alternating administration of cisplatin/etoposide and topotecan in patients with previously untreated extensive-stage smallcell lung cancer (SCLC). PATIENTS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9185d36307b686cfb76943aa3107a09e
https://doi.org/10.3816/clc.2005.n.034
https://doi.org/10.3816/clc.2005.n.034
Autor:
Konstantinos Kalbakis, George Samonis, Aristidis Polyzos, E Tselepatiotis, V. Georgoulias, Kostas N. Syrigos, Athanasios Athanasiadis, D. Mavroudis, M. Agelidou, J Nikolakopoulos, Nikos Androulakis, Aggeliki Rapti, A Agelidou
Publikováno v:
British Journal of Cancer
The aim of this study was to compare the irinotecan/cisplatin regimen with cisplatin as second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) pretreated with a taxane/gemcitabine regimen. Patients (n = 147) with stage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2e70cf3c6e4f60e6c9d7fcddfb35b37
http://europepmc.org/articles/PMC2361638
http://europepmc.org/articles/PMC2361638
Autor:
Charalambos Kouroussis, Michael Toumbis, Charalambos Christofilakis, Emilia Tsaroucha, Konstantinos N. Syrigos, M. Agelidou, A. Agelidou, Nicolaos Ziras, Vassilis Georgoulias, Nikolaos Samaras, Athanasios Alegakis, Alexandros Ardavanis, Pavlos Papakotoulas, Vassilis Chandrinos, Aristidis Polyzos
Publikováno v:
Journal of Clinical Oncology. 22:2602-2609
Purpose To compare the overall survival (OS) of patients with advanced non–small-cell lung cancer (NSCLC) treated with docetaxel plus cisplatin (DC) or docetaxel (D) alone. Patients and Methods Chemotherapy-naïve patients with advanced/metastatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53125a9e6c9b279a963591b20c828a4d
https://doi.org/10.1200/jco.2004.11.004
https://doi.org/10.1200/jco.2004.11.004
Autor:
D Mavroudis, M Veslemes, Ch Kouroussis, N Tzanakis, E Ferdoutsis, M Toumbis, P Ziotopoulos, M Agelidou, E Tselepatiotis, K Kalbakis, J Souglakos, E Magkanas, G Samonis, V Georgoulias, for the Hellenic Oncology Research Group
Publikováno v:
Lung Cancer. 38:59-63
Purpose: In order to investigate the feasibility of a potentially non-cross resistant drug regimen, we alternated cycles of cisplatin–etoposide with topotecan as front-line treatment in patients with extensive stage small cell lung cancer (SCLC). P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a3cecc1d8e37481f603e79135af0908
https://doi.org/10.1016/s0169-5002(02)00149-6
https://doi.org/10.1016/s0169-5002(02)00149-6
Autor:
D. Mavroudis, E. Papadakis, M. Veslemes, X. Tsiafaki, J. Stavrakakis, C. Kouroussis, S. Kakolyris, E. Bania, J. Jordanoglou, M. Agelidou, J. Vlachonicolis, V. Georgoulias
Publikováno v:
Annals of Oncology. 12:463-470
Background: Previous phase I-II studies have shown that the combination of paclitaxel-cisplatin etoposide (TEP) is very active and well tolerated in patients with small-cell lung cancer (SCLC). In order to compare the TEP combination to cisplatin eto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d402143c4b2549d75aaea003ce4bc94
https://doi.org/10.1023/a:1011131303391
https://doi.org/10.1023/a:1011131303391